Overview

A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects

Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine if HBOC-201 is safe and tolerable to trauma subjects, when given to treat the inadequate supply of blood and nutrients to tissues and organs.
Phase:
Phase 2
Details
Lead Sponsor:
Biopure Corporation
Treatments:
HBOC 201